906088-96-8

Upstream product

• 446-17-3 2,4,5-trifluorobenzoic acid 
• 88419-56-1 2,4,5-trifluorobenzoyl chloride 
• 98349-24-7 ethyl 2,4,5-trifluorobenzoylacetate 
• 101799-75-1 α-(ethoxymethylene)-2,4,5-trifluoro-β-oxobenzenepropanoic acid, ethyl ester 
• 875712-88-2 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-isobutyryloxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 875712-88-2 (E)-1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-isobutyryloxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 875712-88-2 (Z)-1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-isobutyryloxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 

Downstream Products

• 352458-37-8 1-(6-amino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxy-1-azetidinyl)-4-oxo-3-quinolinecarboxylic acid 1-deoxy-1-(methylamino)-D-glucitol 
• 442526-91-2 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-isobutyryloxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 
• 189279-58-1 delafloxacin 

Relevant academic research and scientific papers

Refining method of ciprofloxacin and meglumine hydrochloride thereof

The invention provides a preparation process of ciprofloxacin and meglumine thereof. The intermediate product DLSX07 is stirred at Branson ° C. 20% minutes and then sonicated until the solution is cloudy, stirred at room temperature for a period 30s, stirred at room temperature 3h, cooled and slowly added to distilled water, and filtered through suction filtration and filter cake vacuum drying to obtain a pale yellow powder, and 4% the KOH mixture is subjected to ultrasonic treatment 40 - 50 °C. 1. The process is performed by stirring 5h. NCS .t. The solution is cloudy. LC-MS / MS detection powder is deltafloxacin, distilled water is added, and meglumine is mixed to obtain a deltafloxacin meglumine salt. By optimizing the preparation process, the use of the organic solvent is reduced, the reaction time is shortened, and the ice bath and the addition of the interface carrier material contribute to the improvement of the yield.

Preparation of deller floxacin and intermediate thereof

The invention relates to preparation of deller floxacin and an intermediate thereof. According to the preparation method of the deller floxacin, the purity of an intermediate compound, a compound A-3and a compound W-4 is limited to be more than 99.0 perce

Chlorination at the 8-position of a functionalized quinolone and the synthesis of quinolone antibiotic ABT-492

The total synthesis of quinolone antibiotic ABT-492 has been achieved in 67% yield over nine steps from 2,4,5-trifluorobenzoic acid. The highlights of this synthesis include a novel chemoselective chlorination at the 8-position of a highly elaborated quinolone core. In addition, a Lewis acid promoted cyclization reaction to form the quinolone heterocycle was developed which was incorporated into a one-pot, three-step cyclization/coupling/protection sequence that proceeds in 93% yield.

Synthesis of the quinolone ABT-492: Crystallizations for optimal processing

ABT-492 has been under development at Abbott Laboratories as a quinolone antibiotic. A convergent syntheses was utilized to prepare the compound on a multi-kilogram scale. Difficulties in isolation of intermediates were overcome by developing control of t

PREPARATION OF PYRIDONECARBOXYLIC ACID ANTIBACTERIALS

A process for making 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid, and therapeutically acceptable salts thereof, and intermediates used in the process are disclosed.